IYXI (IYXI) Stock Price & Analysis
IYXI (IYXI) rose 0.00% to USD 0 as of June 10, 2026 at 14:16 UTC, according to Nexqual real-time market data.
IYXI last closed at USD 0; the session ranged USD 0–0 on volume of 5,000 shares. Market capitalization is $26,553, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 14:16 UTC.
Key Statistics (as of June 10, 2026 at 14:16 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 5,000 shares |
| Market Cap | $26,553 |
| Exchange | PNK |
Technical Analysis (IYXI)
Nexqual's technical model rates IYXI "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 14:16 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (IYXI)
Wall Street analysts rate IYXI "None", per Nexqual as of June 10, 2026 at 14:16 UTC.
| Consensus Rating | None |
|---|
Earnings (IYXI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2006-09-30 | USD -0.19 vs est -0.13 ▼ miss |
| 2006-06-30 | USD -0.13 vs est -0.09 ▼ miss |
| 2006-03-31 | USD -0.06 vs est -0.05 ▼ miss |
Source: Nexqual, June 10, 2026 at 14:16 UTC.
Financials & Fundamentals (IYXI)
| Total Revenue | $85.04M |
|---|---|
| Revenue Growth (YoY) | +39.50% |
| Gross Margin | +35.49% |
| Operating Margin | -26.30% |
| Profit Margin | -43.66% |
| Current Ratio | 0.26 |
| Total Cash | $1.52M |
| Total Debt | $119.36M |
| Free Cash Flow | $-9.70M |
Source: Nexqual, June 10, 2026 at 14:16 UTC.
Financial Health Score (IYXI)
Nexqual rates IYXI's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 14:16 UTC.
| Growth | Strong — Revenue +40% YoY (latest Q) |
|---|---|
| Profitability | Weak — Gross margin 35%, operating -26% |
| Balance Sheet | Mixed — $2M cash vs $119M debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Mixed — No data |
Ownership (IYXI)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 0 |
Source: Nexqual, June 10, 2026 at 14:16 UTC.
Leadership (IYXI)
IYXI is led by Steven Handley (age 61), President & Director, per Nexqual as of June 10, 2026 at 14:16 UTC.
| President & Director | Steven Handley (age 61) |
|---|---|
| Executive VP, Director of Corporate Development & Director | Jay M. Green (age 75) |
| Vice President of Corporate Communications & Investor Relations | William Kelly |
| Vice President of Sales & Marketing and Commercial Development | Stephen Beckman (age 58) |
Major Backers & Investors (IYXI)
Notable institutional backers of IYXI include FRANK FUNDS-Camelot Event Driven Fund, according to Nexqual as of June 10, 2026 at 14:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FRANK FUNDS-Camelot Event Driven Fund | 0.32% |
Source: Nexqual, June 10, 2026 at 14:16 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QMDT | QUICK-MED TECHNOLOGIES INC | USD 0 | ▲ 0% |
| AOLS | AEOLUS PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| MRPI | MERA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| GSAC | GelStat Corp. | USD 0 | ▲ 0% |
| NNBP | NANOBAC PHARMACEUTICALS INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:16 UTC. This page is informational and not investment advice.